Corrigendum to “De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel”
Titel:
Corrigendum to “De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel”
Auteur:
Nitz, U.A. Gluz, O. Christgen, M. Grischke, E.-M. Augustin, D. Kuemmel, S. Braun, M. Potenberg, J. Kohls, A. Krauss, K. Stefek, A. Schumacher, C. Forstbauer, H. Reimer, T. Fischer, H. Liedtke, C. Wuerstlein, R. Schumacher, J. Kates, R. Kreipe, H. Harbeck, N.